Theravance Biopharma Company Profile (NASDAQ:TBPH)

About Theravance Biopharma

Theravance Biopharma logoTheravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company's pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: TBPH
  • CUSIP:
Key Metrics:
  • Previous Close: $33.54
  • 50 Day Moving Average: $33.60
  • 200 Day Moving Average: $25.78
  • 52-Week Range: $47,851,000.00 - $12.87
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.20
  • P/E Growth: -0.02
  • Market Cap: $1.60B
  • Outstanding Shares: 47,851,000
  • Beta: 2.23
  • Net Margins: -471.82%
  • Return on Equity: -70.79%
  • Return on Assets: -59.26%
  • Current Ratio: 6.79%
  • Quick Ratio: 6.57%
Additional Links:
Companies Related to Theravance Biopharma:

Analyst Ratings

Consensus Ratings for Theravance Biopharma (NASDAQ:TBPH) (?)
Ratings Breakdown: 2 Sell Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $35.00 (4.35% upside)

Analysts' Ratings History for Theravance Biopharma (NASDAQ:TBPH)
DateFirmActionRatingPrice TargetDetails
10/21/2016Leerink SwannSet Price TargetBuy$35.00View Rating Details
10/12/2016Robert W. BairdDowngradeNeutral -> Underperform$19.00 -> $24.00View Rating Details
9/19/2016GuggenheimReiterated RatingPositive$40.00View Rating Details
8/29/2016Evercore ISIInitiated CoverageBuy$41.00View Rating Details
8/3/2016Bank of America Corp.DowngradeNeutral -> UnderperformView Rating Details
(Data available from 10/23/2014 forward)


Earnings History for Theravance Biopharma (NASDAQ:TBPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2016Q216($1.05)($1.06)$12.73 millionViewN/AView Earnings Details
5/9/2016Q116($0.96)($1.10)$18.69 million$18.40 millionViewN/AView Earnings Details
3/9/2016Q415($1.62)($1.23)($280,000.00) million$3.90 millionViewN/AView Earnings Details
11/9/2015Q315($1.44)($1.40)$4.24 million$10.70 millionViewN/AView Earnings Details
8/10/2015Q215($1.51)($1.42)$4.25 million$7.10 millionViewListenView Earnings Details
3/10/2015Q414($1.70)($2.02)$2.01 million$1.30 millionViewN/AView Earnings Details
11/6/2014Q3 14($1.85)($1.72)ViewN/AView Earnings Details
8/14/2014($0.56)($1.83)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Theravance Biopharma (NASDAQ:TBPH)
Current Year EPS Consensus Estimate: $-3.95 EPS
Next Year EPS Consensus Estimate: $-4.09 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($1.20)($1.20)($1.20)
Q3 20161($1.01)($1.01)($1.01)
Q4 20161($0.92)($0.92)($0.92)
(Data provided by Zacks Investment Research)


Dividend History for Theravance Biopharma (NASDAQ:TBPH)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Theravance Biopharma (NASDAQ:TBPH)
Insider Ownership Percentage: 4.70%
Institutional Ownership Percentage: 69.97%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/25/2016Brett K HaumannSVPSell4,491$27.99$125,703.09View SEC Filing  
8/22/2016Bradford J ShaferEVPSell49,122$27.46$1,348,890.12View SEC Filing  
8/19/2016Brett K HaumannSVPSell9,509$27.97$265,966.73View SEC Filing  
3/14/2016Plc GlaxosmithklineMajor ShareholderBuy1,301,015$23,028,000.00$29,959,773,420,000.00View SEC Filing  
10/7/2015Plc GlaxosmithklineMajor ShareholderBuy44,574$607,544.00$27,080,666,256.00View SEC Filing  
8/18/2015Burton G MalkielDirectorBuy10,000$12.92$129,200.00View SEC Filing  
8/18/2015Junning LeeVPBuy9,000$12.90$116,100.00View SEC Filing  
8/17/2015Renee D GalaCFOBuy10,000$12.18$121,800.00View SEC Filing  
8/17/2015Rick E WinninghamCEOBuy80,000$11.86$948,800.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Theravance Biopharma (NASDAQ:TBPH)
DateHeadline logoTheravance Biopharma (TBPH) Will Present VIBATIV Data at Upcoming Conference; Includes TOUR Study Numbers (NASDAQ:TBPH) - October 19 at 10:50 AM logoTheravance Biopharma, Inc. breached its 50 day moving average in a Bearish Manner : TBPH-US : October 17, 2016 (NASDAQ:TBPH) - October 17 at 10:52 AM logoAfter-hours buzz: GPS, HON & more (NASDAQ:TBPH) - October 6 at 7:19 PM logoTheravance Biopharma (TBPH) Announces Dosing of First Patient in TD-1473 Phase 1b as Ulcerative Colitis Treatment (NASDAQ:TBPH) - October 5 at 7:26 PM logoTHERAVANCE BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement (NASDAQ:TBPH) - October 4 at 7:05 PM logoETF’s with exposure to Theravance Biopharma, Inc. : October 3, 2016 (NASDAQ:TBPH) - October 3 at 7:03 PM
News IconTheravance Biopharma - Chart Of The Day (NASDAQ:TBPH) - September 21 at 11:44 AM logoTheravance Biopharma (TBPH) Announces Significant Data from Pivotal Phase 3 FULFIL Study (NASDAQ:TBPH) - September 7 at 7:44 PM logoTheravance Biopharma Highlights Positive Results From Pivotal Phase 3 FULFIL Study of the Closed Triple Announced by GlaxoSmithKline and Innoviva at ERS International Congress (NASDAQ:TBPH) - September 7 at 7:44 PM logoLightstone Ventures Adds Susan Molineaux as Scientific Advisor (NASDAQ:TBPH) - September 7 at 11:22 AM
News IconTheravance Biopharma To Present At 2016 Global Healthcare Conference (NASDAQ:TBPH) - September 2 at 7:29 PM logoTheravance Biopharma to Present at the Baird 2016 Global Healthcare Conference (NASDAQ:TBPH) - September 1 at 7:36 PM logoOne REIT and Three Healthcare Companies See Insiders Buying and Selling Stock (NASDAQ:TBPH) - August 23 at 12:13 PM logoETF’s with exposure to Theravance Biopharma, Inc. : August 18, 2016 (NASDAQ:TBPH) - August 18 at 7:57 PM logoTHERAVANCE BIOPHARMA, INC. Financials (NASDAQ:TBPH) - August 17 at 8:02 PM logoTracking Seth Klarman's Baupost Group Holdings - Q2 2016 Update (NASDAQ:TBPH) - August 13 at 10:31 AM logoTheravance Biopharma, Inc. :TBPH-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:TBPH) - August 12 at 10:57 AM
News IconTheravance Biopharma Reports Second Quarter 2016 Financial Results And Provides Business Update (NASDAQ:TBPH) - August 9 at 8:01 PM logoEdited Transcript of TBPH earnings conference call or presentation 8-Aug-16 9:00pm GMT (NASDAQ:TBPH) - August 9 at 11:01 AM logoTHERAVANCE BIOPHARMA, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:TBPH) - August 9 at 11:01 AM logoTheravance Bio reports 2Q loss (NASDAQ:TBPH) - August 8 at 7:56 PM logoQ2 2016 Theravance Biopharma Inc Earnings Release - After Market Close (NASDAQ:TBPH) - August 8 at 10:50 AM logoTheravance Biopharma downgraded by BofA/Merrill (NASDAQ:TBPH) - August 3 at 8:04 PM logoTheravance Biopharma to Report Second Quarter 2016 Financial Results on August 8, 2016 (NASDAQ:TBPH) - August 1 at 7:30 PM logoCommit To Buy Theravance Biopharma At $20, Earn 14.2% Annualized Using Options (NASDAQ:TBPH) - July 29 at 7:55 PM logoTheravance Biopharma, Inc. breached its 50 day moving average in a Bearish Manner : TBPH-US : July 22, 2016 (NASDAQ:TBPH) - July 22 at 8:16 AM
News IconTBPH-Trek-6450-Clinical-Trial-Press-Release-Final_102715 (NASDAQ:TBPH) - July 20 at 10:38 AM logoTheravance Biopharma Announces New Employment Inducement Awards (NASDAQ:TBPH) - July 7 at 7:46 PM logoTheravance Biopharma to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference (NASDAQ:TBPH) - July 6 at 4:21 PM logoGSK FULFILS Goals, CDXC Sinks On Short Seller Report, LPTN Up On Defense Grant (NASDAQ:TBPH) - June 21 at 10:26 AM logoTheravance Biopharma Highlights Positive Top-Line Results From Pivotal Phase 3 FULFIL Study of the Closed Triple Announced by GlaxoSmithKline and Innoviva (NASDAQ:TBPH) - June 20 at 7:42 PM logoNew Data Shows Potent in vitro Activity of VIBATIV(R) (telavancin) Against Difficult-to-Treat Clinical Pathogens, Including MRSA (NASDAQ:TBPH) - June 20 at 9:10 AM logoTHERAVANCE BIOPHARMA, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:TBPH) - June 14 at 8:02 AM logoTheravance Biopharma to Present New Data Highlighting Potent in vitro Activity of VIBATIV(R) (telavancin) Against Difficult-to-Treat, Clinical Pathogens, Including MRSA, at ASM Microbe 2016 Conference (NASDAQ:TBPH) - June 13 at 8:29 AM logoTheravance Biopharma (TBPH) Says TD-1473 Well Tolerated in Phase 1 Clinical Trial (NASDAQ:TBPH) - June 10 at 10:47 AM logoTheravance Biopharma Signs Licensing Deal with Takeda (NASDAQ:TBPH) - June 9 at 10:48 AM logoTheravance Biopharma Reports Positive Results From Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor (NASDAQ:TBPH) - June 9 at 10:48 AM logoTakeda Licenses Global Rights to Theravance Biopharma's TD-8954, a Novel 5-HT4 Agonist and Motility Agent for Gastrointestinal Motility Disorders (NASDAQ:TBPH) - June 8 at 8:29 AM logoGlaxo/Innoviva Expedite Closed Triple Combination NDA Filing (NASDAQ:TBPH) - June 3 at 9:40 AM logoTheravance Biopharma Highlights Acceleration of Timeline for Filing U.S. New Drug Application for the Closed Triple by GlaxoSmithKline and Innoviva (NASDAQ:TBPH) - June 2 at 7:35 PM logoNo Objection To EverSweet, CTRV Awaits Data In Q4, Two Down, One To Go For DERM (NASDAQ:TBPH) - June 2 at 10:55 AM logoTheravance Biopharma Completes Enrollment in All Three Phase 3 Clinical Studies of Revefenacin (TD-4208) for Treatment of Chronic Obstructive Pulmonary Disease (COPD) (NASDAQ:TBPH) - June 1 at 8:33 AM logoCan the Uptrend Continue for Theravance Biopharma (TBPH)? (NASDAQ:TBPH) - April 8 at 8:29 AM logo7:30 am Theravance Biopharma presents positive preclinical study results for TD-1473 (NASDAQ:TBPH) - March 18 at 7:30 AM logoTheravance Biopharma Presents Positive Results From a Preclinical Colitis Model for TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor (NASDAQ:TBPH) - March 18 at 7:30 AM logoWhy You Shouldn't Bet Against Theravance Biopharma (TBPH) Stock (NASDAQ:TBPH) - March 16 at 8:52 AM logoTheravance Biopharma, Inc. :TBPH-US: Earnings Analysis: Q4, 2015 By the Numbers (NASDAQ:TBPH) - March 14 at 12:33 PM logoTHERAVANCE BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition (NASDAQ:TBPH) - March 9 at 4:23 PM logoTheravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2015 Financial Results (NASDAQ:TBPH) - March 9 at 4:15 PM logoTheravance Biopharma Announces Positive Results Including Biomarker Data From Phase 1 Study of TD-0714, an Inhibitor of Neprilysin (NEP) (NASDAQ:TBPH) - March 9 at 7:30 AM


Theravance Biopharma (NASDAQ:TBPH) Chart for Sunday, October, 23, 2016

Last Updated on 10/23/2016 by Staff